Its interesting to read Lions comments in light of the Operational Update from July 27, 2016. Specifically, the statement regarding the engagement of a group of international drug discovery and preclinical development experts to review scientific and strategic plans.
Although opaque from the outside a number of events have happened since the announcement of the resignation of the CEO. Normally within a corporate vacuum one would expect pessimism, then alarm, followed by a rush to the exits. Instead we have had a progress report on the iMYC cancer program, the commencement of a new Material Transfer Agreement and the renewal of an existing MTA. The CSO who helped pioneer the science has seen fit to step aside into a new role as Chief Scientific Advisor and NED.
In light of anything contrary, the Chairs comment at the time of Hopkin's resignation rings true - Phylogica is entering into the next phase of development and path to commercialisation of the Phylomer Peptide libraries.
PYC Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)